Infection risks during longterm rituximab therapy change over time

Journal of Rheumatology

Volumn 40, Issue 2, 2013, Pages 203-

  Besada, Emilio ^a,b   Nossent, Johannes C ^a  

^a University Museum of Tromsø   (Norway)

^b UNIVERSITY HOSPITAL OF NORTH NORWAY   (Norway)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOPHOSPHAMIDE; IMMUNOSUPPRESSIVE AGENT; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; RITUXIMAB;

ANCA ASSOCIATED VASCULITIS; HUMAN; IMMUNE DEFICIENCY; IMMUNOGLOBULIN DEFICIENCY; INFECTION RISK; LETTER; LONG TERM CARE; LYMPHOCYTE DEPLETION; MYCOSIS; NEUTROPENIA; PRIORITY JOURNAL; RETREATMENT; RHEUMATOID ARTHRITIS; VIRUS INFECTION;

ANTI-NEUTROPHIL CYTOPLASMIC ANTIBODY-ASSOCIATED VASCULITIS; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; FEMALE; HUMANS; MALE; REGISTRIES;

EID: 84873582984     PISSN: 0315162X     EISSN: 14992752     Source Type: Journal    
DOI: 10.3899/jrheum.121247     Document Type: Letter

References (8)

1. Roll P, Ostermeier E, Haubitz M, Lovric S, Unger L, Holle J, et al. Efficacy and safety of rituximab treatment in patients with antineutrophil cytoplasmic antibody-associated vasculitides: Results from a German Registry (GRAID). J Rheumatol 2012;39:2153-6.
2. Kelesidis T, Daikos G, Boumpas D, Tsiodras S. Does rituximab increase the incidence of infectious complication? A narrative review. Int J Infect Dis 2011;15:e2-16.
3. Wendt M, Gunnarson I, Bratt J, Bruchfeld A. Rituximab in relapsing or refractory ANCA-associated vasculitis: A case series of 16 patients. Scand J Rheumatol 2012;41:116-9.
4. Pullerits R, Ljevakt M, Vikgren J, Bokarewa M. Off-trial evaluation of the B cell targeting treatment in the refractory cases of antineutrophil cytoplasmic antibodies (ANCA)-associated vasculitis: Long-term follow-up from a single centre. Scand J Immunol 2012;76:411-20.
5. Samson M, Audia S, Lakomy D, Bonnotte B, Tavernier C, Ornetti P. Diagnostic strategy for patients with hypogammaglobulinemia in rheumatology. Joint Bone Spine 2011;78:241-5.
6. Gottenberg JE, Ravaud P, Bardin T, Cacoub P, Cantagrel A, Combe B, et al; Autoimmunity and Rituximab Registry and French Society of Rheumatology. Risk factors for severe infections in patients with rheumatoid arthritis treated with rituximab in the autoimmunity and rituximab registry. Arthritis Rheum 2010;62:2625-32.
7. Tesfa D, Ajeganova S, Hägglund H, Sander B, Fadeel B, Hafström I, et al. Late-onset neutropenia following rituximab in rheumatic diseases: association with B lymphocytes depletion and infections. Arthritis Rheum 2011;63:2209-14.
8. Besada E, Koldingsnes W, Nossent J. Characteristics of late onset neutropenia in rheumatologic patients treated with rituximab: A case review analysis from a single center. Q J MED 2012; 105:545-50.